Your browser doesn't support javascript.
loading
Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation.
Choi, Seung Hoan; Weng, Lu-Chen; Roselli, Carolina; Lin, Honghuang; Haggerty, Christopher M; Shoemaker, M Benjamin; Barnard, John; Arking, Dan E; Chasman, Daniel I; Albert, Christine M; Chaffin, Mark; Tucker, Nathan R; Smith, Jonathan D; Gupta, Namrata; Gabriel, Stacey; Margolin, Lauren; Shea, Marisa A; Shaffer, Christian M; Yoneda, Zachary T; Boerwinkle, Eric; Smith, Nicholas L; Silverman, Edwin K; Redline, Susan; Vasan, Ramachandran S; Burchard, Esteban G; Gogarten, Stephanie M; Laurie, Cecelia; Blackwell, Thomas W; Abecasis, Gonçalo; Carey, David J; Fornwalt, Brandon K; Smelser, Diane T; Baras, Aris; Dewey, Frederick E; Jaquish, Cashell E; Papanicolaou, George J; Sotoodehnia, Nona; Van Wagoner, David R; Psaty, Bruce M; Kathiresan, Sekar; Darbar, Dawood; Alonso, Alvaro; Heckbert, Susan R; Chung, Mina K; Roden, Dan M; Benjamin, Emelia J; Murray, Michael F; Lunetta, Kathryn L; Lubitz, Steven A; Ellinor, Patrick T.
Afiliação
  • Choi SH; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Weng LC; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Roselli C; Cardiovascular Research Center, Massachusetts General Hospital, Boston.
  • Lin H; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Haggerty CM; National Heart, Lung, and Blood Institute and Boston University's Framingham Heart Study, Framingham, Massachusetts.
  • Shoemaker MB; Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
  • Barnard J; Department of Imaging Science and Innovation, Geisinger, Danville, Pennsylvania.
  • Arking DE; Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Chasman DI; Departments of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
  • Albert CM; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Chaffin M; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Tucker NR; Divisions of Preventive Medicine and Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Smith JD; Divisions of Preventive and Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Gupta N; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Gabriel S; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Margolin L; Cardiovascular Research Center, Massachusetts General Hospital, Boston.
  • Shea MA; Departments of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Shaffer CM; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Yoneda ZT; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Boerwinkle E; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Smith NL; Cardiovascular Research Center, Massachusetts General Hospital, Boston.
  • Silverman EK; Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Redline S; Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Vasan RS; Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston.
  • Burchard EG; Department of Epidemiology and Cardiovascular Health Research Unit, University of Washington, Seattle.
  • Gogarten SM; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Laurie C; Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Blackwell TW; National Heart, Lung, and Blood Institute and Boston University's Framingham Heart Study, Framingham, Massachusetts.
  • Abecasis G; Department of Bioengineering, School of Pharmacy, University of California, San Francisco.
  • Carey DJ; Department of Biostatistics, University of Washington, Seattle.
  • Fornwalt BK; Department of Biostatistics, University of Washington, Seattle.
  • Smelser DT; Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor.
  • Baras A; Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor.
  • Dewey FE; Department of Molecular and Functional Genomics, Geisinger, Danville, Pennsylvania.
  • Jaquish CE; Department of Imaging Science and Innovation, Geisinger, Danville, Pennsylvania.
  • Papanicolaou GJ; Department of Molecular and Functional Genomics, Geisinger, Danville, Pennsylvania.
  • Sotoodehnia N; Regeneron Genetics Center, Tarrytown, New York.
  • Van Wagoner DR; Regeneron Genetics Center, Tarrytown, New York.
  • Psaty BM; Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Kathiresan S; Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Darbar D; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle.
  • Alonso A; Departments of Molecular Cardiology, Cleveland Clinic, Cleveland, Ohio.
  • Heckbert SR; Department of Epidemiology and Cardiovascular Health Research Unit, University of Washington, Seattle.
  • Chung MK; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle.
  • Roden DM; Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
  • Benjamin EJ; Department of Health Services, University of Washington, Seattle.
  • Murray MF; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Lunetta KL; Division of Cardiology, Department of Medicine, University of Illinois, Chicago.
  • Lubitz SA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Ellinor PT; Department of Epidemiology and Cardiovascular Health Research Unit, University of Washington, Seattle.
JAMA ; 320(22): 2354-2364, 2018 12 11.
Article em En | MEDLINE | ID: mdl-30535219
ABSTRACT
Importance Atrial fibrillation (AF) is the most common arrhythmia affecting 1% of the population. Young individuals with AF have a strong genetic association with the disease, but the mechanisms remain incompletely understood.

Objective:

To perform large-scale whole-genome sequencing to identify genetic variants related to AF. Design, Setting, and

Participants:

The National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine Program includes longitudinal and cohort studies that underwent high-depth whole-genome sequencing between 2014 and 2017 in 18 526 individuals from the United States, Mexico, Puerto Rico, Costa Rica, Barbados, and Samoa. This case-control study included 2781 patients with early-onset AF from 9 studies and identified 4959 controls of European ancestry from the remaining participants. Results were replicated in the UK Biobank (346 546 participants) and the MyCode Study (42 782 participants). Exposures Loss-of-function (LOF) variants in genes at AF loci and common genetic variation across the whole genome. Main Outcomes and

Measures:

Early-onset AF (defined as AF onset in persons <66 years of age). Due to multiple testing, the significance threshold for the rare variant analysis was P = 4.55 × 10-3.

Results:

Among 2781 participants with early-onset AF (the case group), 72.1% were men, and the mean (SD) age of AF onset was 48.7 (10.2) years. Participants underwent whole-genome sequencing at a mean depth of 37.8 fold and mean genome coverage of 99.1%. At least 1 LOF variant in TTN, the gene encoding the sarcomeric protein titin, was present in 2.1% of case participants compared with 1.1% in control participants (odds ratio [OR], 1.76 [95% CI, 1.04-2.97]). The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.92 × 10-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P = 1.65 × 10-5). The association between TTN LOF variants and AF was replicated in an independent study of 1582 patients with early-onset AF (cases) and 41 200 control participants (OR, 2.16 [95% CI, 1.19-3.92]; P = .01). Conclusions and Relevance In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group). Further research is necessary to understand whether this is a causal relationship.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Conectina / Mutação com Perda de Função Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Conectina / Mutação com Perda de Função Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2018 Tipo de documento: Article